Frontiers in Cell and Developmental Biology | |
Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy | |
Majid Zamani1  Yoda Yaghoubi2  Mahboubeh Yazdanifar3  Yashwant Pathak5  Max Stanley Chartrand6  Mostafa Jarahian7  Ali Hassanzadeh9  Marwan Mahmood Saleh1,10  Heshu Sulaiman Rahman1,12  Amjad Hussein Altajer1,13  Walid Kamal Abdelbasset1,14  Faroogh Marofi1,15  Dmitry O. Bokov1,16  | |
[1] 0Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Gonabad University of Medical Sciences, Gonabad, Iran;1Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;2Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, United States;3Professor and Associate Dean for Faculty Affairs, Taneja College of Pharmacy, University of South Florida, Tampa, FL, United States;4Adjunct Professor, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia;5DigiCare Behavioral Research, Casa Grande, AZ, United States;6German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), Heidelberg, Germany;College of Medicine, University of Sulaimani, Sulaymaniyah, Iraq;Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran;Department of Biophysics, College of Applied Sciences, University of Anbar, Ramadi, Iraq;Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia;Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaymaniyah, Iraq;Department of Pharmaceutics, College of Pharmacy, Almaaqal University, Basra, Iraq;Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt;Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran;Sechenov First Moscow State Medical University, Moscow, Russia; | |
关键词: mesenchymal stem/stromal cell; gene therapy; chemotherapeutic drug; oncolytic virus; cytokine; pro-drug; | |
DOI : 10.3389/fcell.2021.686453 | |
来源: DOAJ |
【 摘 要 】
Mesenchymal stem/stromal cell (MSC)-based therapy has become an attractive and advanced scientific research area in the context of cancer therapy. This interest is closely linked to the MSC-marked tropism for tumors, suggesting them as a rational and effective vehicle for drug delivery for both hematological and solid malignancies. Nonetheless, the therapeutic application of the MSCs in human tumors is still controversial because of the induction of several signaling pathways largely contributing to tumor progression and metastasis. In spite of some evidence supporting that MSCs may sustain cancer pathogenesis, increasing proofs have indicated the suppressive influences of MSCs on tumor cells. During the last years, a myriad of preclinical and some clinical studies have been carried out or are ongoing to address the safety and efficacy of the MSC-based delivery of therapeutic agents in diverse types of malignancies. A large number of studies have focused on the MSC application as delivery vehicles for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), chemotherapeutic drug such as gemcitabine (GCB), paclitaxel (PTX), and doxorubicin (DOX), prodrugs such as 5-fluorocytosine (5-FC) and ganciclovir (GCV), and immune cell-activating cytokines along with oncolytic virus. In the current review, we evaluate the latest findings rendering the potential of MSCs to be employed as potent gene/drug delivery vehicle for inducing tumor regression with a special focus on the in vivo reports performed during the last two decades.
【 授权许可】
Unknown